Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint

MT Newswires Live2025-03-25

Unity Biotechnology (UBX) shares were down nearly 30% in recent trading on Monday after the company said UBX1325, its diabetic macular edema treatment for patients with poor vision, did not achieve statistical non-inferiority at the primary analysis endpoint in the phase 2b Aspire study.

The company said UBX1325 was non-inferior to aflibercept at week 24 with a confidence interval above 90% but did not meet statistical non-inferiority on the average of weeks 20 and 24, reaching an 88% confidence interval instead of the pre-specified 90% threshold.

Unity Biotechnology posted topline results from all participants through 24 weeks and expects complete 36-week data results in Q2.

Price: 1.28, Change: -0.55, Percent Change: -29.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment